Incyte (INCY) Competitors

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Incyte (NASDAQ:INCY) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, community ranking, media sentiment, risk, earnings, dividends, valuation, profitability and analyst recommendations.

Which has preferable earnings and valuation, ALNY or INCY?

Incyte has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$2.25B	14.54	-$278.16M	-$2.17	-116.36
Incyte	$4.24B	3.26	$32.62M	$0.27	264.37

Do insiders and institutionals hold more shares of ALNY or INCY?

93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. Comparatively, 97.0% of Incyte shares are owned by institutional investors. 1.5% of Alnylam Pharmaceuticals shares are owned by insiders. Comparatively, 17.6% of Incyte shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Does the media prefer ALNY or INCY?

In the previous week, Alnylam Pharmaceuticals had 32 more articles in the media than Incyte. MarketBeat recorded 42 mentions for Alnylam Pharmaceuticals and 10 mentions for Incyte. Incyte's average media sentiment score of 0.97 beat Alnylam Pharmaceuticals' score of 0.40 indicating that Incyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alnylam Pharmaceuticals	19 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Incyte	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts rate ALNY or INCY?

Alnylam Pharmaceuticals presently has a consensus price target of $299.48, indicating a potential upside of 18.61%. Incyte has a consensus price target of $75.59, indicating a potential upside of 5.90%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Alnylam Pharmaceuticals is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	1 Sell rating(s)	5 Hold rating(s)	19 Buy rating(s)	0 Strong Buy rating(s)	2.72
Incyte	1 Sell rating(s)	11 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.35

Which has more risk and volatility, ALNY or INCY?

Alnylam Pharmaceuticals has a beta of 0.35, suggesting that its stock price is 65% less volatile than the S&P 500. Comparatively, Incyte has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500.

Does the MarketBeat Community believe in ALNY or INCY?

Incyte received 83 more outperform votes than Alnylam Pharmaceuticals when rated by MarketBeat users. However, 76.20% of users gave Alnylam Pharmaceuticals an outperform vote while only 72.50% of users gave Incyte an outperform vote.

Company	Underperform	Outperform
Alnylam Pharmaceuticals	Outperform Votes 1143 76.20%	Underperform Votes 357 23.80%
Incyte	Outperform Votes 1226 72.50%	Underperform Votes 465 27.50%

Is ALNY or INCY more profitable?

Incyte has a net margin of 0.77% compared to Alnylam Pharmaceuticals' net margin of -12.37%. Incyte's return on equity of 0.05% beat Alnylam Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	-12.37%	N/A	-6.83%
Incyte	0.77%	0.05%	0.04%

Summary

Incyte beats Alnylam Pharmaceuticals on 12 of the 18 factors compared between the two stocks.